NovaScan Inc.
NovaScan developed a novel, patented technology platform that detects, locates, and stratifies cancer in vivo or ex vivo, in seconds without capital equipment.
- Stage Full Product Ready
- Industry Medical Devices and Equipment
- Location Chicago, IL, USA
- Currency USD
- Founded January 2017
- Employees 8
- Incorporation Type C-corp
- Website novascaninc.com
Company Summary
NovaScan employs machine learning to bio-spectral impedance to detect and assess cancer. NovaScan has two lead products; Canary, to instantly assess oig cancer is present in biopsy cores and MarginScan, to detect cancer in margins of surgical excisions. Company has a commercial partnership with the cancer division of PHC Holdings (formerly Panasonic Health Care) for MarginScan. First candidate is non melanoma skin cancer, launching in late 2025.
Team
-
President and CEO
Craig has a long history in medtech, as an executive, a partner at a family office VC, a partner in Healthios, and as a strategy consultant.. Craig was a senior member GTCR backed team to roll up the urologic device space. He's an ex-partner at Healthios, an investment bank founded by ex-Baxter CEO Vern Loucks. Craig has MBA and MEng from Northwestern, and BSME from Wash U.
-
Founder and Chief Science Officer
Dr. Gregory has spent more than twenty years researching the electrical properties of cells, and he both founded the company and developed much of NovaScan's core intellectual property. He holds numerous patents and is widely published. Previous to founding NovaScan. Bill was the Dean of the College of Engineering and Applied Science at UW-Milwaukee. Dr. Gregory obtained his Ph.D. from MIT and a BA from Georgetown, both in Physics.
-
CTO and VP of Development
Les is an experienced tech leader and manager of engineering teams. He has >20 years of R&D experience with a track record of bringing medical devices to market. He's held positions at Aksys Ltd, Optobionics, Welch Allyn, Zoll Medical and Endotronix. He teaches med device commercialization at University of Illinois at Chicago(UIC). Les has multiple medical device patents and is published in top journals. BS, MS and Ph.D. from UIC; MBA from DePaul
-
Leader, Therapeutics
Dr. Link is an oncologist with deep experience in medical innovation. Dr Link was the CEO, CSO, Chairman and founder of NewLink Genetics, an immunotherapy company that discovered, developed and commercialized novel immuno-oncology product candidates. At its height, NewLink’s market cap was >$1.3B. He led the development of Merck’s EVERBO, the 1st FDA approved Ebola vaccine. His MD is from Stanford and he is an Air Force Academy graduate.
Advisors
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.